---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-26-000039"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:53:53.641776+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports Q4 2025 net loss of $23.6M; advances PLN-101095 Phase 1b after positive ICI-refractory data

## Summary
- PLN-101095 Phase 1: 4 responders (1 CR, 3 PR) out of 10 secondary ICI-refractory patients; IFN-γ biomarker correlated with response.
- Accelerated development: Phase 1b indication expansion trial initiated for NSCLC, RCC, high TMB; first patient enrollment expected Q2 2026.
- Q4 2025 net loss $23.6M vs $49.7M YoY; R&D expense fell to $15.6M from $38.8M due to BEACON-IPF discontinuation.
- Cash, equivalents and short-term investments $192.4M; expected to fund operations into second half 2028.
- Appointed Minnie Kuo as COO; INTEGRIS-PSC Phase 2 results published in Journal of Hepatology (Jan 2026).

## SEC filing metadata
- accession: 0001746473-26-000039
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/0001746473-26-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/plrx-20260311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-26-000039
- JSON: https://secwatch.observer/filing/0001746473-26-000039.json
- Plain text: https://secwatch.observer/filing/0001746473-26-000039.txt

## Key facts
- Earnings Releases
  PLIANT THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income $23.6 million.
  - Period: fourth quarter ended December 31, 2025
  - Net income: $23.6 million
  - Result: reported results
  source text: Net loss was $23.6 million as compared to $49.7 million for the prior-year quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/0001746473-26-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.